Beigene, Ltd. (NASDAQ:ONC) Insider Xiaodong Wang Sells 41,760 Shares

Beigene, Ltd. (NASDAQ:ONC) insider Xiaodong Wang sold 41,760 shares of Beigene stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $261.28, for a total value of $10,911,052.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Xiaodong Wang also recently made the following trade(s):

• On Tuesday, March 4th, Xiaodong Wang sold 8,146 shares of Beigene stock. The shares were sold at an average price of $254.58, for a total value of $2,073,808.68.

Beigene Trading Down 1.4 %

ONC stock opened at $262.59 on Friday. The stock has a market cap of $25.83 billion, a price-to-earnings ratio of -31.87, a P/E/G ratio of 7.73 and a beta of 0.65. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. Beigene, Ltd. has a 52-week low of $126.97 and a 52-week high of $287.88.

Beigene (NASDAQ:ONC) last released its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.09 billion. On average, equities research analysts anticipate that Beigene, Ltd. will post -5.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ONC has been the subject of several research reports. Macquarie raised their target price on Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Guggenheim restated a “buy” rating on shares of Beigene in a research note on Friday, February 28th. JMP Securities set a $348.00 target price on Beigene in a research note on Friday, February 28th. Bank of America upgraded Beigene from a “neutral” rating to a “buy” rating and raised their target price for the company from $207.00 to $320.00 in a research note on Monday, March 3rd. Finally, Sanford C. Bernstein set a $259.00 target price on Beigene in a research note on Thursday, March 13th.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.